Company profile
Avivagen Inc.
OTC: VIVXF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Ottawa, ONReports USD
#905 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 34
v0.1 · 5/100 weight · pillars only
↑ Piotroski F, listing tenure · ↓ Altman-Z, return on assets
Methodology →Revenue TTM
$535.9k
Rev growth YoY (TTM)
-12.8%
Net income (FY)
-$4.7M
Employees
13
as of 2026-08-30
Market cap
$7.8k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$729.5k939.2k CAD2022
Net income-$4.7M-6.1M CAD2022
Operating income-$3.8M-4.9M CAD2022
Total assets$1.0M1.4M CAD2022
Liabilities$5.4M7.3M CAD2022
Equity-$4.4M-6.0M CAD2022
Revenue trend
FY2017 – FY2022 · USD
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Avivagen Inc.’s revenue?
Avivagen Inc. booked $729.5k in FY2022 revenue, contracting 29% year over year — slower than 76% of Healthcare companies we track, at a -645.9% net margin.
Peers · Healthcare
Bio Green Med Solution, Inc.48DWearable Health Solutions, Inc.——Dogecoin Cash, Inc.39DRelevium Technologies Inc.——Applied Biosciences Corp.——Lexaria Bioscience Corp.44DKey facts
CEOG. F. Kym Anthony
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersOttawa, ON
ExchangeOTC: VIVXF
Employees13
IPO date2013-05-02
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.